Molecular Partners Shows Promising Early Data for DLL3-Targeting Radiotherapy MP0712
Event summary
- Molecular Partners presented first patient imaging and dosimetry data for MP0712 at TWC 2026, showing specific tumor accumulation and favorable biodistribution.
- Data from five patients in a Named Patient Access Program in South Africa support the clinical development of MP0712 for DLL3-expressing cancers.
- Phase 1/2a study of MP0712 in the U.S. is ongoing, with initial clinical data expected in 2026.
- Molecular Partners will host a conference call on February 2, 2026, with nuclear medicine expert Prof. Ken Herrmann.
The big picture
Molecular Partners' presentation of early data for MP0712 underscores the potential of DLL3-targeting radiopharmaceuticals in treating small cell lung cancer and other neuroendocrine malignancies. The company's Radio-DARPin platform aims to address historic limitations of radioligand therapy, positioning it as a key player in the evolving landscape of targeted cancer treatments. The strategic collaboration with Orano Med further bolsters Molecular Partners' ability to deliver potent alpha-emitting radioisotopes to solid tumors.
What we're watching
- Clinical Validation
- Whether the Phase 1/2a study data will confirm the promising early results and support further development of MP0712.
- Market Positioning
- How Molecular Partners will leverage the Radio-DARPin platform to compete in the targeted radiopharmaceutical space.
- Regulatory Pathway
- The pace at which Molecular Partners can advance MP0712 through clinical trials and potential regulatory approval.
Related topics